
Pembrolizumab is the first anti-PD-1/anti-PD-L1 therapy to demonstrate a recurrence-free survival benefit in the adjuvant setting for melanoma.

Pembrolizumab is the first anti-PD-1/anti-PD-L1 therapy to demonstrate a recurrence-free survival benefit in the adjuvant setting for melanoma.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discusses the current treatment strategies for C. diff infection and recurrent C. diff infection, as well as the efficacy and safety of these treatments.

In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, explains what the gut-brain axis is and how microbiome impacts this connection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the role of the microbiome in overall patient health and recurrent Clostridioides difficile infection.

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections.

Clonidine, Estradiol, Fentanyl, and Scopolamine are involved most frequently, an ISMP review shows.

Daratumumab continued to demonstrate deep and durable responses, including improvements to stringent complete response (sCR) rates and minimal residual disease (MRD)-negativity.

Studies are currently underway to determine the impact of the Omicron COVID-19 variant on the long-acting antibody combination.

Saol Therapeutics also announces the acquisition of 4 plasma-derived hyperimmune products by Kamada, which will be invested to help launch Lyvispah and other pipeline developments.

Axicabtagene ciloleucel (Yescarta) was the first CAR T-cell immunotherapy to be approved for relapsed or refractory large B-cell lymphoma.

Fulvestrant is also the only SERD approved for patients with breast cancer, according to the researchers.

Pharmacists can play an important role in avoiding common medication errors for patients receiving direct oral anticoagulants.

Olaparib is a first-in-class PARP inhibitor and is the first targeted treatment to block DNA damage response in cells or tumors with a deficiency in homologous recombination repair.

The investigators found that modeling was a cost-effective method for determining the functionality of the proposed blueprint by transforming it into a physical space.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

Although barcode scanning during product verification has greatly improved the safety of medication dispensing operations, many products aren’t easily incorporated into traditional dose preparation processes, including medications manually dispensed in oral syringes.

Acalabrutinib is a Bruton tyrosine kinase inhibitor (BTKi) intended for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

The investigators found that the ability to track the status of a medication in real-time may assist with communication gaps between departments and facilitate patient safety improvements.

Based on experience with other variants, Pfizer and BioNTech have high confidence that if needed, they can deliver an Omicron-based COVID-19 vaccine in March 2022.

Timely access to cancer treatment improves patient outcomes.

The investigators said that there were no new safety signals identified, and no reported instances of tumor lysis syndrome.

The panelists reviewed current treatments for Clostridioides difficile infection and how they can be applied to special patient populations, as well as what treatments can be expected in the future.

Rivaroxaban and apixaban are the most commonly prescribed direct oral anticoagulants, although they may be most effective in different populations.

Lodise discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

As some of the nation’s leading pharmaceutical and biotech giants ramp up product development and commercialization, what was once a futuristic concept has become a reality.

Amid the current shortage in the pharmacy technician workforce, career ladder programs could improve pharmacy technician recruitment and retention rates.

Using a non-aqueous vehicle and sweeteners to improve palatability, pharmacists and technicians can ensure that young patients remain medication adherent.

Results highlight sustained benefits of avapritinib in patients with advanced systemic mastocytosis.

Ten quiz questions to assess your knowledge on common symptoms and treatments for endometrial cancer.